Novartis AG: PharmaVitae Profile
Datamonitor, November 2010, Pages: 129
Introduction
This analysis examines the historical and forecast performance for Novartis in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Novartis's strategic outlook across the next 6 years.
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Highlights
Strategic insight into the prospects for Novartis over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Novartis's performance against key rivals in the prescription pharmaceutical sector
- Assess how Novartis is forecast to deliver the strongest prescription pharmaceutical sales growth of any Big Pharma company over the period 2009-15.
- Analyse Novartis's 'focused diversification' strategy based on its presence in the branded, generic, vaccine, eyecare and consumer health segments.
ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Data sourcing
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Novartis: PharmaVitae forecasts at a glance
Strategic insight
SWOT analysis
Chapter 3 Quarterly update
Latest quarterly sales
Latest quarterly financial analysis
Latest comment
Latest prescription pharma product news
Latest corporate news
Chapter 4 Company introduction
Key findings
Background
Key corporate developments
M&A history
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Chapter 7 Key products
Overview
Chapter 8 Appendix
References
Abbreviations
Exchange rates
About Datamonitor
Datamonitor consulting
Disclaimer
TABLE OF TABLES
Table 1: Novartis – PharmaVitae forecasts at a glance
Table 2: Novartis quarterly sales ($m), Q309–Q310
Table 3: Novartis quarterly financials ($m), Q309-Q310
Table 4: Novartis product portfolio overview ($m), 2003–09
Table 5: Novartis product portfolio overview ($m), 2009–15
Table 6: Novartis prescription pharmaceutical sales by therapy area ($m), 2009–15
Table 7: Novartis prescription pharmaceutical sales by geographic region ($m), 2009–15
Table 8: Novartis launch portfolio overview ($m), 2009–15
Table 9: Novartis core portfolio overview ($m), 2009–15
Table 10: Novartis expiry portfolio overview ($m), 2009–15
Table 11: Novartis (Sandoz) generics portfolio overview ($m), 2009–15
Table 12: Novartis prescription pharmaceutical sales by molecule type ($m), 2009–15
Table 13: Novartis prescription pharmaceutical sales by source ($m), 2009–15
Table 14: Total Novartis sales by business unit ($m), 2003–09
Table 15: Novartis operating revenue/cost analysis ($m), 2003–09
Table 16: Novartis operating cost ratio analysis (% of total revenues), 2003–09
Table 17: Novartis operating cost ratio analysis (% of total revenues), 2009–15
Table 18: Novartis operating revenue/cost analysis ($m), 2009–15
Table 19: Novartis Key products overview
Table 20: Glivec/Gleevec: overview
Table 21: Glivec/Gleevec: sales forecast ($m), 2009–15
Table 22: Gilenia: overview
Table 23: Gilenia: sales forecast ($m), 2009–15
Table 24: QMF149: overview
Table 25: QMF149: sales forecast ($m), 2009–15
Table 26: QVA149: overview
Table 27: QVA149: sales forecast ($m), 2009–15
Table 28: Tasigna: overview
Table 29: Tasigna: sales forecast ($m), 2009–15
Table 30: Diovan: overview
Table 31: Diovan: sales forecast ($m), 2009–15
Table 32: Co-Diovan: overview
Table 33: Co-Diovan: sales forecast ($m), 2009–15
Table 34: Zometa: overview
Table 35: Zometa: sales forecast ($m), 2009–15
Table 36: Femara: overview
Table 37: Femara: sales forecast ($m), 2009–15
Table 38: Sandostatin: overview
Table 39: Sandostatin: sales forecast ($m), 2009–15
Table 40: Exchange rates, 2010
TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer
Figure 2: Novartis prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15
Figure 3: Novartis’s financial performance ($m), 2003–15
Figure 4: Novartis prescription pharmaceutical sales growth by business area ($m), 2009-15
Figure 5: Novartis prescription pharmaceutical sales growth by business area (branded portfolio segmented) ($m), 2009-15
Figure 6: Sandoz corporate structure demonstrating diverse growth opportunities
Figure 7: Sandoz M&A driven geographic expansion ($m), 2003-15
Figure 8: Synergies between Alcon and Novartis
Figure 9: Novartis SWOT analysis
Figure 10: Sandoz M&A history, 2001-09
Figure 11: Novartis prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15
Figure 12: Novartis Key product sales ($m), 2003–15
Figure 13: Novartis key sales growth drivers and resistors ($m), 2003–09
Figure 14: Novartis key sales growth drivers and resistors ($m), 2009–15
Figure 15: Novartis prescription pharmaceutical sales by therapy area ($m), 2003–15
Figure 16: Novartis prescription pharmaceutical sales by geographic region ($m), 2003–15
Figure 17: Novartis launch/core/expiry configuration ($m), 2009–15
Figure 18: Novartis prescription pharmaceutical sales by molecule type ($m), 2003–15
Figure 19: Novartis prescription pharmaceutical sales by source ($m), 2003-15
Figure 20: Novartis operating revenue/cost analysis ($m), 2003–15
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
